All In Biotech

Drug Trial Radar · NCT06997627

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

An Open(Part 1), Single-arm(Part 1), Randomized(Part 2), Double-blind(Part 2), Active-controlled(Part 2) Phase I/II Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of GC3111B in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 5, 2025

Primary completion

May 2026

Study completion May 2026

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
May 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.

Conditions

  • Tetanus-diphtheria-acellular Pertussis (Tdap)

Interventions

  • GC3111BBiological

    0.5 mL, Intramuscular injection

  • Boostrix®Biological

    0.5 mL, Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Solicited adverse events occurring by day 14 after administration of the investigational productTime frame: 14 days after administration of the IP
  2. Unsolicited adverse events occurring by day 28 after administration of the investigational productTime frame: 28 days after administration of the IP
  3. Acute adverse events occurring within 30 minutes after administration of the investigational productTime frame: 30 minutes after administration of the IP
  4. Serious adverse events (SAE) and adverse events of special interest (AESI) occurring up to 180 days after administration of the investigational productTime frame: 180 days after administration of the IP
  5. Clinically significant findings in vital signs, laboratory tests, 12-lead electrocardiograms, and physical examinationsTime frame: 28 days after administration of the IP

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.